Undisclosed IL-2muFc mutant fusion protein
/ Almirall
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 14, 2026
Advancing a broad Medical Dermatology pipeline
(Businesswire)
- "In 2026, Almirall plans to initiate 3 additional PoC clinical studies with an anti-IL-21 mAb targeting hidradenitis suppurativa and one additional inflammatory skin disease for the anti-IL-1RAP and the IL-2muFc mutant fusion protein, respectively. Furthermore, Almirall plans to advance a bispecific antibody targeting both IL-13 and OX-40L for the treatment of atopic dermatitis into Phase I in the first half of 2026."
New P1 trial • New P3 trial • Atopic Dermatitis • Hidradenitis Suppurativa
1 to 1
Of
1
Go to page
1